stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Return on equity
Scholar Rock Holding Corporation's return on equity over the twelve months to 30 June 2026 was −167.8%, down 44.7 percentage points from fiscal 2025 (−123.1%). Over the past ten years it has ranged from −185.8% (fiscal 2018) to 59.8% (fiscal 2017); the current reading is higher than 20% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −123.1% | (40.13) |
| FY2024 | −83.0% | (14.65) |
| FY2023 | −68.3% | (6.08) |
| FY2022 | −62.2% | (1.32) |
| FY2021 | −60.9% | (14.61) |
| FY2020 | −46.3% | 0.17 |
| FY2019 | −46.5% | 139.32 |
| FY2018 | −185.8% | (245.61) |
| FY2017 | 59.8% | 21.03 |
| FY2016 | 38.8% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| MANE Veradermics Incorporated compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| CGON CG Oncology, Inc. compare | −26.4% |
| ERAS Erasca, Inc. compare | −78.3% |
| IMVT Immunovant, Inc. compare | −80.1% |
| COGT Cogent Biosciences, Inc. compare | −146.6% |
| SRRK Scholar Rock Holding Corporation | −167.8% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement